Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ainos, Inc. filings document operating results, material agreements, governance matters, and the securities structure of a Nasdaq-listed company with AIMD common stock and AIMDW warrants. Form 8-K reports cover annual and quarterly financial results, AI Nose commercialization updates, distribution rights for AINOS AI Nose products and services, and amendments to product-development and patent-use arrangements.
The company’s proxy materials disclose director elections, shareholder voting matters, compensation information, and governance procedures. Its filings also describe relationships involving Taiwan Carbon Nano Technology Corporation and Ainos KY, including control and voting-power matters relevant to the company’s corporate governance and development agreements.
Ainos, Inc. reported second-quarter 2026 results, highlighting ongoing commercialization of its AI Nose Smell AI platform while remaining deeply loss-making. Revenue for the quarter ended June 30, 2026 was $152, down from $4,663 a year earlier; six-month revenue was $313 versus $110,870 in 2025.
The company recorded a Q2 2026 net loss of $(4,594,731) compared with $(4,084,990) in Q2 2025, and a six-month net loss of $(7,054,531) versus $(7,371,012). Basic and diluted net loss per share was $(0.62) for the quarter and $(1.05) year-to-date. Cash and cash equivalents increased to $1,422,912 at June 30, 2026 from $417,353 at December 31, 2025.
Balance sheet leverage rose, with current liabilities of $16,277,500 including $11,000,000 of current convertible notes and a $2,812,940 loan payable. Total stockholders’ equity declined to $3,283,985, driven by an accumulated deficit of $(74,574,859). Management emphasized expanding AI Nose deployments, an initial $2.1 million backend semiconductor arrangement, and datasets totaling approximately 613 million industrial smell records to support its Smell AI platform.
Ainos, Inc., a Texas-based developer of AI-enabled olfactory sensing (AI Nose) and immune therapeutics, reported very limited revenue while remaining deeply loss-making for the quarter and six months ended June 30, 2026. Revenue was $152 in Q2 2026 and $313 in H1 2026, down sharply from $4,663 and $110,870 a year earlier as the company reduced VELDONA pet supplement sales and shifted AI Nose efforts toward industrial rather than healthcare-adjacent applications.
Net loss totaled $4.6M for Q2 2026 and $7.1M for H1 2026, compared with $4.1M and $7.4M in the prior-year periods, as operating expenses eased to $6.7M from $7.0M. Basic and diluted net loss per share was $0.62 for Q2 and $1.05 for H1 2026. Cash and cash equivalents increased to $1.4M at June 30, 2026 from $0.4M at December 31, 2025, mainly driven by a $2.8M short-term loan from ASE Test, Inc. and $0.6M of net equity raised under an at-the-market offering.
Total assets were $19.6M, while stockholders’ equity fell to $3.3M from $7.6M. Current liabilities rose to $16.3M, including $11.0M of convertible notes now classified as current and the new loan payable. With an accumulated deficit of $74.6M, ongoing operating losses, and dependence on external financing, the company states that substantial doubt exists about its ability to continue as a going concern. Operationally, Ainos continued to advance AI Nose deployments and validation in semiconductor manufacturing, robotics, industrial infrastructure, and healthcare environments, including work tied to an initial $2.1M backend semiconductor commercial arrangement, while progressing its VELDONA interferon programs selectively and pursuing partnering and out-licensing opportunities.
Ainos, Inc. updated its at-the-market equity program with H.C. Wainwright to permit additional primary issuances of common stock with an aggregate offering price of up to $1,346,165 from time to time under the existing Sales Agreement.
Previously, Ainos sold $2,714,728.20 of securities under this agreement, including $1,960,544 pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-month period. As of July 24, 2026, public float was approximately $9,920,125, based on 8,544,073 shares outstanding and a Nasdaq Capital Market price of $3.16 per share. The company states it will not sell more than one-third of its public float in any 12-month period while its public float remains below $75.0 million, in line with Form S-3 limitations.
Ainos, Inc., a Texas-based company listed on Nasdaq under AIMD and AIMDW, changed its independent registered public accounting firm. On July 9, 2026, the company dismissed YCM CPA INC. following expiration of its engagement and, on the same day, the audit committee engaged DLEE Accountancy, Inc. as the new independent registered public accounting firm.
The company states it had no disagreements with YCM on accounting principles, financial statement disclosure, or auditing scope or procedures, and reports no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S‑K. Ainos indicates it did not consult DLEE on potential audit opinions or accounting issues before the engagement. YCM has been asked to provide a letter to the SEC regarding its agreement with these statements.
Ainos, Inc. entered into a General Agreement for Omnibus Credit Lines with CTBC Bank Co., Ltd., providing a short-term unsecured credit facility of NT$62,000,000 (approximately US$1,937,800). Outstanding borrowings bear interest at 2.5% per annum. The facility has a three-month term and matures on September 30, 2026. It is unsecured and includes customary events of default, giving Ainos additional near-term funding flexibility.
Ainos, Inc. director Chiang Yao-chung reported an indirect open-market purchase of 3,500 shares of common stock at $2.05 per share, held in the name of his spouse. Following this transaction, indirect holdings total 11,279 shares, in addition to 90,880 shares directly owned as previously disclosed.
Ainos, Inc. director Chiang Yao-Chung reported an open-market purchase of 2,000 shares of the company’s common stock at $2.13 per share. The shares are held indirectly through the director’s spouse, bringing indirect holdings to 7,779 shares. In addition, the director directly owns 90,880 shares of Ainos common stock as previously disclosed.
Ainos, Inc. director Chiang Yao-chung reported an open-market purchase of 250 shares of common stock at $2.30 per share on behalf of a spouse-held account. After this indirect transaction, that account holds 5,779 shares, while the director also directly owns 90,880 shares of Ainos common stock as previously disclosed.
Ainos, Inc. director Chiang Yao-chung reported an open-market purchase of 2,000 shares of common stock at $2.00 per share on May 27, 2026. The shares are held indirectly through his spouse, bringing indirect holdings to 5,529 shares. A footnote states he also directly owns 90,880 shares of Ainos common stock, indicating this trade is a modest increase to his overall position.
Ainos, Inc. director Lee Ting-Chuan reported an open-market sale of common stock. On May 26, 2026, the director sold 109,988 shares at $1.90 per share to cover income tax obligations, according to the footnote. After this transaction, the director directly holds 807,417 common shares.